Russia OKs Yondelis for ovarian cancer
This article was originally published in Scrip
Executive Summary
Russia has authorised Centocor Ortho Biotech Products (COBP), the Johnson & Johnson subsidiary, to market Yondelis (trabectedin) for the treatment of platinum-sensitive ovarian cancer. It should be used in combination with Caelyx (pegylated liposomal doxorubicin hydrochloride).